Natixis Advisors LLC Sells 9,846 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Natixis Advisors LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 20.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,595 shares of the biopharmaceutical company’s stock after selling 9,846 shares during the period. Natixis Advisors LLC’s holdings in Cytokinetics were worth $1,985,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. J.Safra Asset Management Corp raised its stake in Cytokinetics by 642.3% in the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 456 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Cytokinetics by 65.6% during the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 238 shares during the period. Blue Trust Inc. raised its position in shares of Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 680 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Cytokinetics in the 3rd quarter valued at approximately $54,000. Finally, Bessemer Group Inc. boosted its position in shares of Cytokinetics by 25,100.0% during the first quarter. Bessemer Group Inc. now owns 1,260 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 1,255 shares in the last quarter.

Cytokinetics Price Performance

NASDAQ CYTK opened at $50.25 on Tuesday. Cytokinetics, Incorporated has a one year low of $30.68 and a one year high of $110.25. The stock has a 50-day moving average of $53.47 and a 200 day moving average of $54.57. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The company has a market capitalization of $5.93 billion, a price-to-earnings ratio of -9.34 and a beta of 0.78.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $1.21 million. During the same period last year, the firm earned ($1.35) earnings per share. The firm’s revenue was up 22.5% compared to the same quarter last year. On average, sell-side analysts forecast that Cytokinetics, Incorporated will post -5.25 EPS for the current year.

Analyst Ratings Changes

CYTK has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price objective on Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a report on Thursday, September 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research note on Friday, October 18th. The Goldman Sachs Group lowered shares of Cytokinetics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $85.00 to $60.00 in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a research note on Monday, November 18th. Finally, Mizuho lifted their target price on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $83.93.

Insider Activity

In other Cytokinetics news, Director Wendall Wierenga sold 4,452 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $52.25, for a total transaction of $232,617.00. Following the completion of the sale, the director now directly owns 24,559 shares of the company’s stock, valued at approximately $1,283,207.75. This represents a 15.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $50.55, for a total transaction of $252,750.00. Following the completion of the transaction, the chief executive officer now owns 397,456 shares in the company, valued at $20,091,400.80. The trade was a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,078 shares of company stock valued at $3,514,119 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.